地拉罗司进医保了吗？

Thalassemia is a rare genetic disease. In addition to iron removal and blood transfusion, most patients in China use oral dispersible tablets as treatment. Oral deferasirox treatment is far safer and more convenient than blood transfusion, and has fewer side effects. Deferasirox (Enrige) is a drug approved to reduce iron burden, with a recommended starting daily dose of 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (ie, more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. In patients who have already responded well to deferoxamine therapy, an initial dose equivalent to half the deferoxamine dose may be considered. Take it on an empty stomach at least 30 minutes before meals, once a day, preferably at the same time every day.

Deferasirox dispersible tablets can be used in patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. Corresponding to body weight, it is initially recommended to take deferasirox at a daily dose of 20 mg/kg, depending on the improvement of serum ferritin indicators. Usage and dosage are based on the patient's personal condition, constitution, family genetic history, and drug ingredients. The drug is accurately selected to truly prescribe the right medicine for the disease. At the same time, the medicine is accurately administered in the appropriate method, appropriate dose, and appropriate time. Pay attention to drug contraindications, adverse reactions, interactions, etc.

Although the drug Deferasirox is also available in China, it is an imported version originally developed by Novartis and is not covered by medical insurance. Fortunately, India’s Cipla deferasirox is available. Cipla Ltd, India's second-largest drug maker by drug sales, will launch generic products of 20 patented medicines from the world's leading drug manufacturers after securing high-sounding trademarks for its generic brands. Thanks to the local people-friendly pricing policy, the price of Cipla in India is only over $200 equivalent to RMB, which can be described as a truly good medicine!

Recommended related hot articles: /newsDetail/86803.html